{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-044349","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.149369+00:00","generated_at":"2026-05-22T16:53:39.561506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocular Therapeutix Q1 net revenue down 27.6% to $10.7M; cash $349.7M, runway to 2028","bullets":["Net loss of $64.1M ($0.38 per share) vs. $64.8M ($0.49) in Q1 2024; R&D expenses doubled to $42.9M on wet AMD trials.","DEXTENZA sales fell 27.7% to $10.6M due to pricing strategy, MIPS inclusion; quarterly sales expected to rise for rest of 2025.","SOL-1 (Phase 3 wet AMD) topline data on track for 1Q 2026; FDA accepted SPA amendment allowing re-dosing at Weeks 52 and 76.","SOL-R enrollment strong after target cut to ~555 subjects; remains 90% powered for non-inferiority; expedited NDA submission possible.","Positive FDA feedback on potential AXPAXLI registrational trial in NPDR; company planning next steps in NPDR and DME."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-044349","json":"https://secwatch.observer/filing/0001104659-25-044349.json","markdown":"https://secwatch.observer/filing/0001104659-25-044349.md","text":"https://secwatch.observer/filing/0001104659-25-044349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/0001104659-25-044349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/tm2513949d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:53:39.561506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}